Koji Kamikozuru

777 total citations
36 papers, 496 citations indexed

About

Koji Kamikozuru is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Koji Kamikozuru has authored 36 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Genetics, 17 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Koji Kamikozuru's work include Inflammatory Bowel Disease (31 papers), Microscopic Colitis (12 papers) and Immune Cell Function and Interaction (5 papers). Koji Kamikozuru is often cited by papers focused on Inflammatory Bowel Disease (31 papers), Microscopic Colitis (12 papers) and Immune Cell Function and Interaction (5 papers). Koji Kamikozuru collaborates with scholars based in Japan, Belgium and Canada. Koji Kamikozuru's co-authors include Yoko Yokoyama, Shirô Nakamura, Ken Fukunaga, Nobuyuki Hida, Hiroto Miwa, Yoshio Ohda, Masaki Iimuro, Kazuko Nagase, Takayuki Matsumoto and Kōji Yoshida and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and World Journal of Gastroenterology.

In The Last Decade

Koji Kamikozuru

34 papers receiving 493 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Koji Kamikozuru Japan	13	358	258	178	102	52	36	496
Timothy E. Ritter United States	11	279 0.8×	215 0.8×	89 0.5×	110 1.1×	38 0.7×	38	442
AnnKatrin Petersen United States	5	331 0.9×	200 0.8×	105 0.6×	90 0.9×	47 0.9×	12	483
Catherine Van Kemseke Belgium	12	393 1.1×	286 1.1×	141 0.8×	178 1.7×	26 0.5×	25	534
Hiromitsu Ban Japan	10	221 0.6×	143 0.6×	323 1.8×	176 1.7×	67 1.3×	16	570
Ivan Ferkolj Slovenia	11	276 0.8×	193 0.7×	111 0.6×	120 1.2×	48 0.9×	23	416
Alon D. Levin Netherlands	8	237 0.7×	190 0.7×	175 1.0×	100 1.0×	17 0.3×	9	538
Phillip Minar United States	12	317 0.9×	207 0.8×	215 1.2×	84 0.8×	44 0.8×	40	434
Javaid Subhani United Kingdom	6	305 0.9×	211 0.8×	122 0.7×	101 1.0×	24 0.5×	12	466
Veerle J. Nuij Netherlands	10	378 1.1×	271 1.1×	118 0.7×	231 2.3×	29 0.6×	12	538
D. J. Buurman Netherlands	7	244 0.7×	157 0.6×	154 0.9×	50 0.5×	37 0.7×	8	338

Countries citing papers authored by Koji Kamikozuru

Since Specialization

Citations

This map shows the geographic impact of Koji Kamikozuru's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Kamikozuru with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Kamikozuru more than expected).

Fields of papers citing papers by Koji Kamikozuru

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koji Kamikozuru. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Kamikozuru. The network helps show where Koji Kamikozuru may publish in the future.

Co-authorship network of co-authors of Koji Kamikozuru

This figure shows the co-authorship network connecting the top 25 collaborators of Koji Kamikozuru. A scholar is included among the top collaborators of Koji Kamikozuru based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Kamikozuru. Koji Kamikozuru is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fukui, Hirokazu, Toshiyuki Sato, Mikio Kawai, et al.. (2025). Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody. Intestinal Research. 23(4). 464–474.

Fukui, Hirokazu, Tetsuya Shiraishi, Yasuhiro Takagi, et al.. (2025). Continuous Treatment with Tofacitinib but Not Filgotinib Is Effective in Non-Responders with Active Ulcerative Colitis: A Propensity Score-Matching Analysis. Journal of Clinical Medicine. 14(1). 217–217.

Takagi, Yasuhiro, Toshiyuki Sato, Masataka Igeta, et al.. (2025). Real‐World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study. Alimentary Pharmacology & Therapeutics. 61(12). 1923–1934. 4 indexed citations

Feagan, Brian G., Jean–Frédéric Colombel, Remo Panaccione, et al.. (2024). Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease. SHILAP Revista de lepidopterología. 4(1). 100544–100544. 1 indexed citations

Watanabe, Kenji, Mikio Kawai, Toshiyuki Sato, et al.. (2024). Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World Journal of Gastroenterology. 30(13). 1871–1886. 5 indexed citations

Watanabe, Kenji, Mikio Kawai, Koji Fujimoto, et al.. (2020). P648 Efficacy including rapid response and safety of tofacitinib in Japanese patients with ulcerative colitis: A preliminary investigation in a specialised IBD centre. Journal of Crohn s and Colitis. 14(Supplement_1). S535–S535. 3 indexed citations

Watanabe, Kenji, Mikio Kawai, Koji Fujimoto, et al.. (2020). Tu1907 EFFICACY INCLUDING RAPID RESPONSE AND SAFETY OF TOFACITINIB IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS: A PRELIMINARY INVESTIGATION IN A SPECIALIZED IBD CENTER. Gastroenterology. 158(6). S–1213. 1 indexed citations

Miyazaki, Takako, Kenji Watanabe, Koji Fujimoto, et al.. (2019). Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn’s Disease: A Preliminary Study. Digestion. 101(1). 53–59. 15 indexed citations

Yokoyama, Yoko, Hiroshi Tanaka, Akihiro Nishio, et al.. (2017). P150 Pregnancy complications and outcomes in patients with inflammatory bowel disease. Journal of Crohn s and Colitis. 11(suppl_1). S152–S153. 3 indexed citations

10.

Yokoyama, Yoko, Ken Fukunaga, Koji Kamikozuru, et al.. (2014). Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. Cytotherapy. 16(6). 821–825. 6 indexed citations

11.

Nishiumi, Shin, Makoto Ooi, Tomoo Yoshie, et al.. (2014). A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis. Journal of Crohn s and Colitis. 8(9). 1010–1021. 30 indexed citations

12.

Okuyama, Yusuke, Akira Andoh, Ken Fukunaga, et al.. (2013). Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis. Scandinavian Journal of Gastroenterology. 48(4). 412–418. 5 indexed citations

13.

Yokoyama, Yoko, Mikio Kawai, Ken Fukunaga, et al.. (2013). Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterology. 13(1). 27–27. 24 indexed citations

14.

Fukunaga, Ken, Koji Kamikozuru, Shin‐ichiro Kashiwamura, et al.. (2011). Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn' Disease. Gut and Liver. 5(1). 37–45. 21 indexed citations

15.

Yokoyama, Yoko, Ken Fukunaga, Hiroki Ikeuchi, et al.. (2011). The CD4+CD28null and the regulatory CD4+CD25High T-cell phenotypes in patients with ulcerative colitis during active and quiescent disease, and following colectomy. Cytokine. 56(2). 466–470. 21 indexed citations

16.

Yoshida, Kōji, Ken Fukunaga, Hiroki Ikeuchi, et al.. (2011). Scheduled infliximab monotherapy to prevent recurrence of Crohnʼs disease following ileocolic or ileal resection: A 3-year prospective randomized open trial. Inflammatory Bowel Diseases. 18(9). 1617–1623. 106 indexed citations

17.

Yoshida, Kōji, Ken Fukunaga, Hiroki Ikeuchi, et al.. (2010). W1285 Infliximab Mono-Therapy Prevented Post Operative Recurrence of Crohn's Disease After Intestinal Resection: A Prospective Randomized Open Trial in Japanese Population. Gastroenterology. 138(5). S–691. 2 indexed citations

18.

Fukunaga, Ken, Kazuko Nagase, Takeshi Kusaka, et al.. (2009). Cytapheresis in Patients with Severe Ulcerative Colitis after Failure of Intravenous Corticosteroid: A Long-Term Retrospective Cohort Study. Gut and Liver. 3(1). 41–47. 3 indexed citations

19.

Tozawa, Katsuyuki, Ken Fukunaga, Koji Kamikozuru, et al.. (2008). Hyperthermic stimulation of blood increases the immunological effects of granulocyte and monocyte adsorption in vitro: Relevance to extracorporeal immunomodulation. Transfusion and Apheresis Science. 39(2). 129–135. 3 indexed citations

20.

Yokoyama, Yoko, Ken Fukunaga, Yoshihiro Fukuda, et al.. (2007). Demonstration of Low-Regulatory CD25High+CD4+ and High-Pro-inflammatory CD28−CD4+ T-Cell Subsets in Patients with Ulcerative Colitis: Modified by Selective Granulocyte and Monocyte Adsorption Apheresis. Digestive Diseases and Sciences. 52(10). 2725–2731. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact